Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: American Spirit who wrote (17105)	12/21/1999 10:10:00 PM
From: American Spirit	Respond to of 57584

Time to re-buy ISIP? Jubak likes it at five bucks - cheap.FWIW: From Jim Jubak's 12/17 column: "Isis, on the other hand, on Dec. 15 announced disappointing results from clinical trials of its compound ISIS 2302 in Crohn's disease. The results were so disappointing, in fact, that the company has decided not to apply for regulatory approval for the drug. That's a major disappointment for Isis, and probably for investors as well since the stock fell $10 on the news. But the company does have other compounds in advanced trial and the stock at $5 -- the price after the news -- seems excessively cheap. (Full disclosure: I own shares of both Isis and Ligand, and I bought more shares of Isis on the drop.)"